NZ244439A
(en)
*
|
1991-09-25 |
1994-01-26 |
Fisons Plc |
Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
|
US6582728B1
(en)
*
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US6051256A
(en)
*
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
US6428771B1
(en)
*
|
1995-05-15 |
2002-08-06 |
Pharmaceutical Discovery Corporation |
Method for drug delivery to the pulmonary system
|
US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US20020052310A1
(en)
*
|
1997-09-15 |
2002-05-02 |
Massachusetts Institute Of Technology The Penn State Research Foundation |
Particles for inhalation having sustained release properties
|
US6652837B1
(en)
*
|
1996-05-24 |
2003-11-25 |
Massachusetts Institute Of Technology |
Preparation of novel particles for inhalation
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6503480B1
(en)
*
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
CA2275422A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
US20030203036A1
(en)
*
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
EP0971698A4
(en)
|
1996-12-31 |
2006-07-26 |
Nektar Therapeutics |
Aerosolized hydrophobic drug
|
US6126919A
(en)
*
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US7779020B2
(en)
*
|
2002-03-01 |
2010-08-17 |
International Business Machines Corporation |
Small-footprint applicative query interpreter method, system and program product
|
BR9811793A
(en)
*
|
1997-07-18 |
2000-09-26 |
Infimed Inc |
Biodegradable macromers for the controlled release of biologically active substances.
|
US7052678B2
(en)
|
1997-09-15 |
2006-05-30 |
Massachusetts Institute Of Technology |
Particles for inhalation having sustained release properties
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6565885B1
(en)
*
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US6433040B1
(en)
*
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
ZA9811377B
(en)
*
|
1997-12-12 |
1999-08-27 |
Expression Genetics Inc |
Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
|
GB9727102D0
(en)
*
|
1997-12-22 |
1998-02-25 |
Andaris Ltd |
Microparticles and their therapeutic use
|
US6958148B1
(en)
*
|
1998-01-20 |
2005-10-25 |
Pericor Science, Inc. |
Linkage of agents to body tissue using microparticles and transglutaminase
|
CA2231968A1
(en)
*
|
1998-03-11 |
1999-09-11 |
Smoke-Stop, A Partnership Consisting Of Art Slutsky |
Method of producing a nicotine medicament
|
US6284282B1
(en)
|
1998-04-29 |
2001-09-04 |
Genentech, Inc. |
Method of spray freeze drying proteins for pharmaceutical administration
|
US6423345B2
(en)
*
|
1998-04-30 |
2002-07-23 |
Acusphere, Inc. |
Matrices formed of polymer and hydrophobic compounds for use in drug delivery
|
ES2198922T3
(en)
*
|
1998-06-24 |
2004-02-01 |
Advanced Inhalation Research, Inc. |
LARGE POROUS PARTICLES ISSUED BY AN INHALER.
|
EP1273290A1
(en)
*
|
1998-06-24 |
2003-01-08 |
Advanced Inhalation Research, Inc. |
Large porous particles emitted from an inhaler
|
US6956021B1
(en)
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
US7056504B1
(en)
|
1998-08-27 |
2006-06-06 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase I and II
|
MA25590A1
(en)
|
1998-09-14 |
2002-12-31 |
Inhale Therapeutic Syst |
ACTIVE AGENT FOR DRY POWDER DELIVERY
|
US8933032B2
(en)
|
1998-10-20 |
2015-01-13 |
Children's Hospital Medical Center |
Surfactant protein D for the treatment of disorders associated with lung injury
|
CZ298489B6
(en)
*
|
1999-03-05 |
2007-10-17 |
Chiesi Farmaceutici S. P. A. |
Powder for use in a dry powder inhaler
|
US20050214227A1
(en)
*
|
1999-03-08 |
2005-09-29 |
Powderject Research Limited |
Microparticle formulations for sustained-release of bioactive compounds
|
US7412332B1
(en)
|
1999-04-23 |
2008-08-12 |
Massachusetts Institute Of Technology |
Method for analyzing polysaccharides
|
US6428769B1
(en)
*
|
1999-05-04 |
2002-08-06 |
Aradigm Corporation |
Acute testosterone administration
|
EP1187639A1
(en)
*
|
1999-06-04 |
2002-03-20 |
Delrx Pharmaceutical Corporation |
Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
|
US6858199B1
(en)
*
|
2000-06-09 |
2005-02-22 |
Advanced Inhalation Research, Inc. |
High efficient delivery of a large therapeutic mass aerosol
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
PT1196430E
(en)
|
1999-06-29 |
2012-04-18 |
Mannkind Corp |
Purification and stabilization of peptide and protein pharmaceutical agents
|
WO2001013891A2
(en)
*
|
1999-08-25 |
2001-03-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
US7252840B1
(en)
|
1999-08-25 |
2007-08-07 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles
|
US20010036481A1
(en)
*
|
1999-08-25 |
2001-11-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US6586008B1
(en)
|
1999-08-25 |
2003-07-01 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles during spray drying
|
US6749835B1
(en)
|
1999-08-25 |
2004-06-15 |
Advanced Inhalation Research, Inc. |
Formulation for spray-drying large porous particles
|
US6706892B1
(en)
*
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US6156294A
(en)
|
1999-11-28 |
2000-12-05 |
Scientific Development And Research, Inc. |
Composition and method for treatment of otitis media
|
US6676930B2
(en)
|
1999-11-28 |
2004-01-13 |
Scientific Development And Research, Inc. |
Composition and method for treatment of otitis media
|
US6761909B1
(en)
*
|
1999-12-21 |
2004-07-13 |
Rxkinetix, Inc. |
Particulate insulin-containing products and method of manufacture
|
EP1242112A4
(en)
|
1999-12-21 |
2005-02-09 |
Rxkinetix Inc |
Particulate drug-containing products and method of manufacture
|
IL150461A0
(en)
*
|
1999-12-30 |
2002-12-01 |
Chiron Corp |
Methods for pulmonary delivery of interleukin-2
|
AU2001226029A1
(en)
|
2000-01-10 |
2001-07-24 |
Dura Pharmaceuticals, Inc. |
Pharmaceutical formulation and method for pulmonary and oral delivery
|
US7029700B2
(en)
*
|
2000-01-14 |
2006-04-18 |
Brown University Research Foundation |
Micronized freeze-dried particles
|
US7833549B2
(en)
*
|
2000-01-19 |
2010-11-16 |
Mannkind Corporation |
Dry powder formulations of antihistamine for nasal administration
|
DE60142614D1
(en)
*
|
2000-01-27 |
2010-09-02 |
Medimmune Inc |
INITÄT
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
CA2400172C
(en)
|
2000-02-28 |
2010-04-20 |
Genesegues, Inc. |
Nanocapsule encapsulation system and method
|
DK1259547T3
(en)
*
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
|
AU4351201A
(en)
*
|
2000-03-08 |
2001-09-17 |
Massachusetts Inst Technology |
Heparinase iii and uses thereof
|
CA2403690A1
(en)
*
|
2000-03-14 |
2001-09-21 |
National Jewish Medical And Research Center |
Method for reducing allergen-induced airway hyperresponsiveness
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
*
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
PT1280520E
(en)
*
|
2000-05-10 |
2014-12-16 |
Novartis Ag |
Phospholipid-based powders for drug delivery
|
US7575761B2
(en)
*
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
AU2001280934A1
(en)
*
|
2000-07-28 |
2002-02-13 |
Alliance Pharmaceutical Corp. |
Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
|
WO2002009669A2
(en)
*
|
2000-08-01 |
2002-02-07 |
Inhale Therapeutic Systems, Inc. |
Apparatus and process to produce particles having a narrow size distribution and particles made thereby
|
US20060177416A1
(en)
|
2003-10-14 |
2006-08-10 |
Medivas, Llc |
Polymer particle delivery compositions and methods of use
|
PT1319183E
(en)
|
2000-09-12 |
2009-06-29 |
Massachusetts Inst Technology |
Methods and products related to low molecular weight heparin
|
US6613308B2
(en)
*
|
2000-09-19 |
2003-09-02 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
US6514482B1
(en)
|
2000-09-19 |
2003-02-04 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
AU2440802A
(en)
|
2000-10-18 |
2002-04-29 |
Massachusetts Inst Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
GB0028268D0
(en)
*
|
2000-11-20 |
2001-01-03 |
Norske Stats Oljeselskap |
Well treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6818216B2
(en)
*
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
DE60140268D1
(en)
*
|
2000-11-30 |
2009-12-03 |
Vectura Ltd |
PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION
|
US20020128179A1
(en)
*
|
2000-12-01 |
2002-09-12 |
Tacon William C. |
Shaped microparticles for pulmonary drug delivery
|
WO2002043705A2
(en)
*
|
2000-12-01 |
2002-06-06 |
University Of Florida |
Aerodynamically light vaccine for active pulmonary immunization
|
EP2341060B1
(en)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US7247704B2
(en)
|
2000-12-18 |
2007-07-24 |
Arriva Pharmaceuticals, Inc. |
Multifunctional protease inhibitors and their use in treatment of disease
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
WO2002072636A2
(en)
*
|
2000-12-28 |
2002-09-19 |
Altus Biologics Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
CA2433335C
(en)
*
|
2000-12-29 |
2010-04-20 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having sustained release properties
|
US20020141946A1
(en)
*
|
2000-12-29 |
2002-10-03 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
US6749845B2
(en)
*
|
2001-02-15 |
2004-06-15 |
Aeropharm Technology, Inc. |
Modulated release particles for lung delivery
|
US6848197B2
(en)
*
|
2001-04-18 |
2005-02-01 |
Advanced Inhalation Research, Inc. |
Control of process humidity to produce large, porous particles
|
EA007408B1
(en)
*
|
2001-05-21 |
2006-10-27 |
Нектар Терапьютикс |
Pulmonary administration of chemically modified insulin
|
US7498019B2
(en)
|
2001-05-24 |
2009-03-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of compounds for the treatment of headache through an inhalation route
|
US6737042B2
(en)
|
2001-05-24 |
2004-05-18 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US6759029B2
(en)
*
|
2001-05-24 |
2004-07-06 |
Alexza Molecular Delivery Corporation |
Delivery of rizatriptan and zolmitriptan through an inhalation route
|
US20030051728A1
(en)
*
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
US7090830B2
(en)
*
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
DE60230035D1
(en)
|
2001-05-24 |
2009-01-08 |
Alexza Pharmaceuticals Inc |
ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR TRIAZOLAM BY INHALATION
|
US6805853B2
(en)
*
|
2001-11-09 |
2004-10-19 |
Alexza Molecular Delivery Corporation |
Delivery of diazepam through an inhalation route
|
US7458374B2
(en)
*
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
WO2002100357A1
(en)
*
|
2001-06-12 |
2002-12-19 |
Trial Corporation |
Cosmetic
|
JP2005500304A
(en)
*
|
2001-06-21 |
2005-01-06 |
アルタス バイオロジックス インコーポレイテッド |
Spherical protein particles and methods for making and using them
|
US6730772B2
(en)
|
2001-06-22 |
2004-05-04 |
Venkatram P. Shastri |
Degradable polymers from derivatized ring-opened epoxides
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
US6921390B2
(en)
*
|
2001-07-23 |
2005-07-26 |
Boston Scientific Scimed, Inc. |
Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
|
DE10137102A1
(en)
*
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalent vaccine against diseases caused by papillomaviruses, processes for their production and their use
|
GB0118689D0
(en)
*
|
2001-08-01 |
2001-09-19 |
Psimedica Ltd |
Pharmaceutical formulation
|
WO2003024396A2
(en)
|
2001-09-17 |
2003-03-27 |
Glaxo Group Limited |
Dry powder medicament formulations
|
DE60227691D1
(en)
*
|
2001-11-01 |
2008-08-28 |
Nektar Therapeutics |
SPRAY DRYING PROCESS
|
KR20040073438A
(en)
*
|
2001-11-19 |
2004-08-19 |
벡톤 디킨슨 앤드 컴퍼니 |
Pharmaceutical compositions in particulate form
|
US20030129250A1
(en)
*
|
2001-11-20 |
2003-07-10 |
Advanced Inhalation Research Inc. |
Particulate compositions for improving solubility of poorly soluble agents
|
DK1455755T3
(en)
*
|
2001-11-20 |
2013-07-15 |
Civitas Therapeutics Inc |
Improved particle composition for delivery in lung
|
EP1458361A4
(en)
*
|
2001-11-20 |
2007-04-25 |
Advanced Inhalation Res Inc |
Compositions for sustained action product delivery
|
US20030168057A1
(en)
*
|
2001-12-14 |
2003-09-11 |
Inhale Therapeutic Systems, Inc. |
Electronically controllable aerosol delivery
|
SI1458360T1
(en)
|
2001-12-19 |
2011-08-31 |
Novartis Ag |
Pulmonary delivery of aminoglycosides
|
AU2003217950A1
(en)
*
|
2002-03-05 |
2003-09-22 |
Cleveland State University |
Agglomerated particles for aerosol drug delivery
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
WO2003077834A2
(en)
*
|
2002-03-15 |
2003-09-25 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
US20050163725A1
(en)
*
|
2002-03-20 |
2005-07-28 |
Blizzard Charles D. |
Method for administration of growth hormone via pulmonary delivery
|
US7008644B2
(en)
|
2002-03-20 |
2006-03-07 |
Advanced Inhalation Research, Inc. |
Method and apparatus for producing dry particles
|
WO2003079991A2
(en)
*
|
2002-03-20 |
2003-10-02 |
Advanced Inhalation Research, Inc. |
Method for administration of growth hormone via pulmonary delivery
|
CA2479751C
(en)
|
2002-03-20 |
2008-06-03 |
Trent Poole |
Inhalation apparatus
|
ES2389156T3
(en)
*
|
2002-03-20 |
2012-10-23 |
Civitas Therapeutics, Inc. |
Lung administration of levodopa
|
WO2003087189A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Valorisation - Recherche, Societe En Commandite |
Functionalized polymers and their biomedical and pharmaceutical uses
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
*
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
AU2003243191B2
(en)
|
2002-05-02 |
2007-09-20 |
President And Fellows Of Harvard College |
Formulations limiting spread of pulmonary infections
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
CA2483687A1
(en)
|
2002-05-13 |
2003-11-20 |
Alexza Molecular Delivery Corporation |
Delivery of drug amines through an inhalation route
|
US6930137B2
(en)
*
|
2002-05-31 |
2005-08-16 |
Fina Technology, Inc. |
Method of improving blown film processing performance and physical properties
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
*
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
EP1534327A4
(en)
*
|
2002-07-25 |
2006-08-23 |
Medimmune Inc |
Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
|
DE10234165B4
(en)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
A method of filling a trench formed in a substrate with an insulating material
|
EP2371389A3
(en)
|
2002-08-14 |
2012-04-18 |
MacroGenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
CN1694689A
(en)
*
|
2002-09-30 |
2005-11-09 |
阿库斯菲尔公司 |
Sustained release pharmaceutical formulation for inhalation
|
DE60336406D1
(en)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
ANTIBODIES BINDING TO CELL ASSOCIATED CA 125 / 0722P, AND METHOD FOR THEIR USE
|
US6800663B2
(en)
*
|
2002-10-18 |
2004-10-05 |
Alkermes Controlled Therapeutics Inc. Ii, |
Crosslinked hydrogel copolymers
|
ATE420647T1
(en)
|
2002-11-26 |
2009-01-15 |
Alexza Pharmaceuticals Inc |
USE OF LOXAPINE FOR THE PRODUCTION OF A PAIN TREATMENT AGENT
|
US20040105818A1
(en)
*
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
*
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
US20040206350A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Nektar Therapeutics |
Aerosolization apparatus with non-circular aerosolization chamber
|
CA2508870C
(en)
*
|
2002-12-30 |
2012-10-16 |
Nektar Therapeutics |
Prefilming atomizer
|
JP2006513236A
(en)
*
|
2002-12-31 |
2006-04-20 |
ネクター セラピューティクス |
Pharmaceutical formulations with insoluble active substances
|
AU2003302274A1
(en)
*
|
2002-12-31 |
2004-07-29 |
Novartis Ag |
Aerosolizable pharmaceutical formulation for fungal infection therapy
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP2272533A1
(en)
|
2003-01-13 |
2011-01-12 |
MacroGenics, Inc. |
Soluble FcyR fusion proteins and methods of use thereof
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
WO2004073729A1
(en)
*
|
2003-02-21 |
2004-09-02 |
Translational Research Ltd. |
Compositions for nasal administration of drug
|
USRE45404E1
(en)
|
2003-03-27 |
2015-03-03 |
Shin Nippon Biomedical Laboratories, Ltd. |
Powder medicine applicator for nasal cavity
|
US8869794B1
(en)
|
2003-04-09 |
2014-10-28 |
Novartis Pharma Ag |
Aerosolization apparatus with capsule puncturing member
|
ES2383367T5
(en)
*
|
2003-04-09 |
2021-03-31 |
Novartis Ag |
Aerosol spray device with air intake protection
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
US20040234914A1
(en)
|
2003-05-21 |
2004-11-25 |
Alexza Molecular Delivery Corporation |
Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
|
GB0313604D0
(en)
*
|
2003-06-12 |
2003-07-16 |
Britannia Pharmaceuticals Ltd |
Delivery device for powdered medicament
|
WO2004112799A1
(en)
*
|
2003-06-13 |
2004-12-29 |
Chrysalis Technologies Incorporated |
Methods and apparatus for producing nanoscale particles
|
EP1635762B1
(en)
|
2003-06-13 |
2021-03-03 |
Civitas Therapeutics, Inc. |
Low dose pharmaceutical powders for inhalation
|
US20050032173A1
(en)
*
|
2003-08-05 |
2005-02-10 |
Mauricio Rojas |
Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
|
BR0318454A
(en)
|
2003-08-08 |
2006-09-12 |
Abgenix Inc |
parathyroid hormone (pth) targeting antibodies and their uses
|
US7318925B2
(en)
*
|
2003-08-08 |
2008-01-15 |
Amgen Fremont, Inc. |
Methods of use for antibodies against parathyroid hormone
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
EP2272566A3
(en)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisation of antibodies
|
CA2538237A1
(en)
*
|
2003-09-10 |
2005-03-24 |
Map Pharmaceuticals, Inc. |
Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
US7943179B2
(en)
*
|
2003-09-23 |
2011-05-17 |
Massachusetts Institute Of Technology |
pH triggerable polymeric particles
|
AU2004277419B2
(en)
*
|
2003-09-30 |
2007-10-11 |
Brown University Research Foundation |
Nanoparticulate therapeutic biologically active agents
|
CA2533887A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Acusphere, Inc. |
Injectable, oral, or topical sustained release pharmaceutical formulations
|
US20070160622A1
(en)
*
|
2005-12-07 |
2007-07-12 |
Medivas, Llc |
Method for assembling a polymer-biologic delivery composition
|
WO2006088647A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Medivas, Llc |
Polymer particle delivery compositions and methods of use
|
US7338171B2
(en)
*
|
2003-10-27 |
2008-03-04 |
Jen-Chuen Hsieh |
Method and apparatus for visual drive control
|
US20050214224A1
(en)
*
|
2003-11-04 |
2005-09-29 |
Nektar Therapeutics |
Lipid formulations for spontaneous drug encapsulation
|
CN101027082A
(en)
*
|
2004-01-12 |
2007-08-29 |
曼恩坎德公司 |
Method of reducing serum proinsulin levels in type 2 diabetics
|
US20060019914A1
(en)
*
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US20050207983A1
(en)
|
2004-03-05 |
2005-09-22 |
Pulmatrix, Inc. |
Formulations decreasing particle exhalation
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
US7279457B2
(en)
*
|
2004-03-12 |
2007-10-09 |
Biodel, Inc. |
Rapid acting drug delivery compositions
|
JP2007536273A
(en)
*
|
2004-05-07 |
2007-12-13 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
Lung malaria vaccine
|
US7727962B2
(en)
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
US7723306B2
(en)
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
US7611709B2
(en)
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
EP1755720A1
(en)
*
|
2004-05-20 |
2007-02-28 |
Discovery Laboratories, Inc. |
Methods , systems and devices for noninvasive pulmonary delivery
|
US7540286B2
(en)
*
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
AU2005258040A1
(en)
*
|
2004-06-21 |
2006-01-05 |
Novartis Ag |
Compositions comprising amphotericin b
|
US8513204B2
(en)
*
|
2004-06-21 |
2013-08-20 |
Novartis Ag |
Compositions comprising amphotericin B, mehods and systems
|
RU2007106714A
(en)
*
|
2004-07-26 |
2008-09-10 |
Байер Шеринг Фарма Аг (De) |
TREATMENT OF PULMONARY HYPERTENSION BY INHALATION OF ILOPROSTAT WITH A MICROPARTICLES PREPARATION
|
JP4922762B2
(en)
*
|
2004-08-10 |
2012-04-25 |
株式会社新日本科学 |
Composition for nasal administration that is fast-acting and capable of high absorption
|
WO2006022714A1
(en)
*
|
2004-08-12 |
2006-03-02 |
Alexza Pharmaceuticals, Inc. |
Aerosol drug delivery device incorporating percussively activated heat packages
|
US20100006092A1
(en)
*
|
2004-08-12 |
2010-01-14 |
Alexza Pharmaceuticals, Inc. |
Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
|
ES2385934T3
(en)
|
2004-08-20 |
2012-08-03 |
Mannkind Corporation |
CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
|
KR101644250B1
(en)
*
|
2004-08-23 |
2016-07-29 |
맨카인드 코포레이션 |
Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
|
CA2580921C
(en)
|
2004-09-21 |
2016-04-12 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1812068A4
(en)
*
|
2004-10-29 |
2010-06-09 |
Medimmune Inc |
Methods of preventing and treating rsv infections and related conditions
|
DE102004053373A1
(en)
*
|
2004-11-02 |
2006-05-04 |
Justus-Liebig-Universität Giessen |
Invention relating to nano / meso-fiber anisometric particles in the form of nano / meso-fiber tubes, cables and their curved or branched modifications
|
US8337815B2
(en)
*
|
2004-12-23 |
2012-12-25 |
Discovery Laboratories, Inc. |
Pulmonary surfactant formulations
|
US8627821B2
(en)
|
2005-01-10 |
2014-01-14 |
Pulmatrix, Inc. |
Method and device for decreasing contamination
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US8028697B2
(en)
|
2005-04-28 |
2011-10-04 |
Trudell Medical International |
Ventilator circuit and method for the use thereof
|
AU2006247077A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Pulmatrix Inc. |
Formulations for alteration of biophysical properties of mucosal lining
|
WO2006128025A2
(en)
*
|
2005-05-23 |
2006-11-30 |
Children's Hospital Medical Center |
Regulatory proteins in lung repair and treatment of lung disease
|
US20070031342A1
(en)
*
|
2005-06-22 |
2007-02-08 |
Nektar Therapeutics |
Sustained release microparticles for pulmonary delivery
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
US7700739B2
(en)
*
|
2005-06-30 |
2010-04-20 |
Abbott Laboratories |
IL-12/p40 binding proteins
|
US7919583B2
(en)
*
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
EP1913127A2
(en)
*
|
2005-08-11 |
2008-04-23 |
The President and Fellows of Harvard College |
Methods and compositions for dried cellular forms
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CN101370525B
(en)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
Dual variable domain immunoglobin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
DK1928423T3
(en)
|
2005-09-14 |
2016-02-29 |
Mannkind Corp |
A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
|
WO2007038246A2
(en)
*
|
2005-09-22 |
2007-04-05 |
Medivas, Llc |
Solid polymer delivery compositions and methods for use thereof
|
WO2007035938A2
(en)
|
2005-09-22 |
2007-03-29 |
Medivas, Llc |
BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
|
WO2007036501A2
(en)
*
|
2005-09-26 |
2007-04-05 |
Basf Aktiengesellschaft |
Graft copolymer and use of the same
|
US7713929B2
(en)
|
2006-04-12 |
2010-05-11 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
CA2623256A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Nektar Therapeutics |
Receptacles and kits, such as for dry powder packaging
|
US8084420B2
(en)
*
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2007041481A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Biodel, Inc. |
Rapid acting and prolonged acting insulin preparations
|
ES2542501T3
(en)
*
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use
|
EP1954246A4
(en)
*
|
2005-11-11 |
2012-01-18 |
Biolab Sanus Farmaceutica Ltda |
Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
|
WO2008048298A2
(en)
*
|
2005-11-21 |
2008-04-24 |
Medivas, Llc |
Polymer particles for delivery of macromolecules and methods of use
|
EP2289909B1
(en)
*
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
|
CN102898519B
(en)
*
|
2005-11-30 |
2015-10-28 |
Abbvie公司 |
Monoclonal antibody of anti-amyloid beta protein and uses thereof
|
EP1978933A2
(en)
*
|
2005-12-15 |
2008-10-15 |
Acusphere, Inc. |
Processes for making particle-based pharmaceutical formulations for oral administration
|
WO2007070851A2
(en)
*
|
2005-12-15 |
2007-06-21 |
Acusphere, Inc. |
Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
|
US8039431B2
(en)
|
2006-02-22 |
2011-10-18 |
Mannkind Corporation |
Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
|
WO2007123777A2
(en)
*
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
CA2648291A1
(en)
*
|
2006-04-04 |
2007-11-01 |
Stc.Unm |
Swellable particles for drug delivery
|
MX2008013165A
(en)
*
|
2006-04-12 |
2009-01-29 |
Biodel Inc |
Rapid acting and long acting insulin combination formulations.
|
WO2007124131A2
(en)
*
|
2006-04-20 |
2007-11-01 |
The University Of North Carolina At Chapel Hill |
Hybrid nanomaterials as multimodal imaging contrast agents
|
JP5445130B2
(en)
*
|
2006-05-02 |
2014-03-19 |
メディバス エルエルシー |
Delivery of ophthalmic drugs to the exterior or interior of the eye
|
WO2007133616A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Medivas, Llc |
Biodegradable water soluble polymers
|
EP2505209A1
(en)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-specific antibodies and methods of the use thereof
|
BRPI0716088B8
(en)
|
2006-08-28 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
isolated antibody, composition, isolated nucleic acid molecule, vector, method for producing an antibody, hybridoma, and kit
|
HUE052220T2
(en)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin -13 binding proteins
|
EP2064335A4
(en)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8337817B2
(en)
|
2006-12-26 |
2012-12-25 |
Shin Nippon Biomedical Laboratories, Ltd. |
Preparation for transnasal application
|
DK2148691T3
(en)
|
2007-02-05 |
2015-08-17 |
Apellis Pharmaceuticals Inc |
Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
|
PL2425820T3
(en)
*
|
2007-02-11 |
2015-08-31 |
Map Pharmaceuticals Inc |
Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
|
US8895004B2
(en)
*
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
US20080216828A1
(en)
|
2007-03-09 |
2008-09-11 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
WO2008124522A2
(en)
*
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
WO2008137747A1
(en)
|
2007-05-02 |
2008-11-13 |
The Regents Of The University Of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
SG194368A1
(en)
|
2007-05-04 |
2013-11-29 |
Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa |
Engineered rabbit antibody variable domains and uses thereof
|
PE20090329A1
(en)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
CA2691434C
(en)
|
2007-06-21 |
2020-07-21 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CA2709412A1
(en)
*
|
2007-07-24 |
2009-01-29 |
Medivas, Llc |
Biodegradable cationic polymer gene transfer compositions and methods of use
|
CA2694488A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
GB0715376D0
(en)
*
|
2007-08-07 |
2007-09-19 |
Smith & Nephew |
Coating
|
JP5270884B2
(en)
*
|
2007-09-03 |
2013-08-21 |
大阪瓦斯株式会社 |
Dispersant and polylactic acid based composite resin particles containing the dispersant
|
EP2033971A1
(en)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
US20090175840A1
(en)
*
|
2008-01-04 |
2009-07-09 |
Biodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
US20110105995A1
(en)
*
|
2008-01-16 |
2011-05-05 |
Zhu Ting F |
Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
|
BRPI0907046A2
(en)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
|
US20110135571A1
(en)
*
|
2008-02-22 |
2011-06-09 |
Wenbin Lin |
Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
JP5507539B2
(en)
|
2008-03-17 |
2014-05-28 |
ディスカバリー ラボラトリーズ、インク. |
Ventilation circuit adapter and proximal aerosol delivery system
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
JP5890174B2
(en)
|
2008-05-09 |
2016-03-22 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
Antibody against terminal glycation end product receptor (RAGE) and use thereof
|
WO2009140587A1
(en)
|
2008-05-15 |
2009-11-19 |
Novartis Ag |
Pulmonary delivery of a fluoroquinolone
|
RU2010153580A
(en)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
|
US9109026B2
(en)
*
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
AU2009257311B2
(en)
|
2008-06-13 |
2014-12-04 |
Mannkind Corporation |
A dry powder inhaler and system for drug delivery
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
WO2009155450A2
(en)
*
|
2008-06-20 |
2009-12-23 |
Board Of Regents, The University Of Texas System |
Biodegradable photoluminescent polymers
|
US9364619B2
(en)
|
2008-06-20 |
2016-06-14 |
Mannkind Corporation |
Interactive apparatus and method for real-time profiling of inhalation efforts
|
BRPI0915825A2
(en)
|
2008-07-08 |
2015-11-03 |
Abbott Lab |
prostaglandin binding proteins and uses thereof
|
MX2010014574A
(en)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof.
|
WO2010008564A2
(en)
*
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Plaice dna transposon system
|
TWI532497B
(en)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
Use of ultrarapid acting insulin
|
JP2012500207A
(en)
*
|
2008-08-13 |
2012-01-05 |
メディバス エルエルシー |
AABB-poly (depsipeptide) biodegradable polymer and method of use
|
US20100092526A1
(en)
*
|
2008-09-26 |
2010-04-15 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US8596265B2
(en)
|
2008-10-22 |
2013-12-03 |
Trudell Medical International |
Modular aerosol delivery system
|
WO2010057197A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
US20100233079A1
(en)
*
|
2008-12-04 |
2010-09-16 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
CN106220734A
(en)
|
2008-12-19 |
2016-12-14 |
宏观基因有限公司 |
Covalent diabodies and application thereof
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
BRPI1007371A2
(en)
*
|
2009-01-29 |
2018-03-27 |
Abbott Lab |
il-1 binding proteins
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US20120064166A1
(en)
*
|
2009-02-18 |
2012-03-15 |
Bayer Pharma Aktienesellschaft |
Formulation comprising drospirenone for subcutaneous or intramuscular administration
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
TWI541021B
(en)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Il-17 binding proteins
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
JP5667095B2
(en)
|
2009-03-11 |
2015-02-12 |
マンカインド コーポレイション |
Apparatus, system and method for measuring inhaler resistance
|
PL2413902T3
(en)
|
2009-03-18 |
2020-01-31 |
Incarda Therapeutics, Inc. |
Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
|
RU2577698C2
(en)
|
2009-03-26 |
2016-03-20 |
Пулмэтрикс, Инк. |
Dry powder formulations and methods of treating pulmonary diseases
|
WO2010111132A2
(en)
|
2009-03-27 |
2010-09-30 |
Bend Research, Inc. |
Spray-drying process
|
DE102009016119A1
(en)
*
|
2009-04-03 |
2010-10-14 |
Evonik Degussa Gmbh |
Nutritional supplement containing alpha-keto acids to support diabetes therapy
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
WO2010131486A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal pharmaceutical compositions with improved pharmacokinetics
|
AU2010254551B2
(en)
|
2009-05-27 |
2016-10-20 |
Selecta Biosciences, Inc. |
Immunomodulatory agent-polymeric compounds
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
CA2764505C
(en)
|
2009-06-12 |
2018-09-25 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
ES2880102T3
(en)
*
|
2009-06-12 |
2021-11-23 |
Mannkind Corp |
Dicetopiperazine microparticles with defined isomer content
|
JP5918129B2
(en)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
Engineered Fc region for site-specific conjugation
|
US20110171141A1
(en)
*
|
2009-06-26 |
2011-07-14 |
Kellerman Donald J |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2011013003A2
(en)
*
|
2009-07-31 |
2011-02-03 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal granisetron and nasal applicator
|
KR101778317B1
(en)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
Antibodies against human respiratory syncytial virus(rsv) and methods of use
|
CN105131112A
(en)
|
2009-08-29 |
2015-12-09 |
Abbvie公司 |
Therapeutic dll4 binding proteins
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2486141B1
(en)
|
2009-10-07 |
2018-01-10 |
MacroGenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
CN102666875A
(en)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
Dual variable domain immunoglobulins and uses thereof
|
GB0918450D0
(en)
*
|
2009-10-21 |
2009-12-09 |
Innovata Ltd |
Composition
|
UY32979A
(en)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
US8420083B2
(en)
*
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011056889A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
US8449916B1
(en)
*
|
2009-11-06 |
2013-05-28 |
Iowa State University Research Foundation, Inc. |
Antimicrobial compositions and methods
|
AU2010329955A1
(en)
|
2009-12-08 |
2012-05-24 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
|
KR20180044441A
(en)
|
2010-03-02 |
2018-05-02 |
애브비 인코포레이티드 |
Therapeutic dll4 binding proteins
|
NZ602054A
(en)
|
2010-03-17 |
2014-10-31 |
Abbott Res Bv |
Anti-nerve growth factor (ngf) antibody compositions
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
SG185416A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
CA2798390A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
LT2571532T
(en)
|
2010-05-14 |
2017-08-10 |
Abbvie Inc. |
Il-1 binding proteins
|
NO2575876T3
(en)
|
2010-05-26 |
2018-05-05 |
|
|
RU2571331C1
(en)
|
2010-06-21 |
2015-12-20 |
Маннкайнд Корпорейшн |
Systems and methods for dry powder drug delivery
|
CA2800206C
(en)
|
2010-06-25 |
2018-06-05 |
(Inserm) Institut National De La Sante Et De La Recherche Medicale |
Methods and pharmaceutical compositions for the treatment of respiratory tract infections
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
TWI627964B
(en)
|
2010-07-09 |
2018-07-01 |
傑森疫苗防護公司 |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
UY33492A
(en)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
EP2601216B1
(en)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
PE20131412A1
(en)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
PT3333188T
(en)
|
2010-08-19 |
2022-03-28 |
Zoetis Belgium S A |
Anti-ngf antibodies and their use
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
CN103080134B
(en)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
The antibody of EGF-R ELISA 3 (HER3)
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2012030664A1
(en)
|
2010-08-30 |
2012-03-08 |
Pulmatrix, Inc. |
Dry powder formulations and methods for treating pulmonary diseases
|
US8758824B2
(en)
|
2010-08-30 |
2014-06-24 |
Pulmatrix, Inc. |
Respirably dry powder comprising calcium lactate, sodium chloride and leucine
|
US9084944B2
(en)
|
2010-09-03 |
2015-07-21 |
Bend Research, Inc. |
Spray-drying apparatus and methods of using the same
|
US8815294B2
(en)
|
2010-09-03 |
2014-08-26 |
Bend Research, Inc. |
Pharmaceutical compositions of dextran polymer derivatives and a carrier material
|
WO2012031129A2
(en)
|
2010-09-03 |
2012-03-08 |
Bend Research, Inc. |
Spray-drying apparatus and methods of using the same
|
US9248584B2
(en)
|
2010-09-24 |
2016-02-02 |
Bend Research, Inc. |
High-temperature spray drying process and apparatus
|
DK2621488T3
(en)
|
2010-09-29 |
2019-03-04 |
Pulmatrix Operating Co Inc |
CATIONIC DRY POWDER
|
AU2011308865B2
(en)
|
2010-09-29 |
2017-01-05 |
Pulmatrix, Inc. |
Monovalent metal cation dry powders for inhalation
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
PE20141060A1
(en)
|
2010-12-21 |
2014-09-26 |
Abbvie Inc |
IL-1 ALPHA AND BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND THEIR USE
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
CN105667994B
(en)
|
2011-04-01 |
2018-04-06 |
曼金德公司 |
Blister package for pharmaceutical kit
|
HUE037651T2
(en)
|
2011-04-20 |
2018-09-28 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
EP2723361B1
(en)
|
2011-06-22 |
2019-10-30 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
CN103748139B
(en)
|
2011-06-23 |
2016-08-17 |
帝斯曼知识产权资产管理有限公司 |
For delivering the micron particle comprising biodegradable polyester-amide copolymer or the nano-particle of bioactivator
|
US9873765B2
(en)
|
2011-06-23 |
2018-01-23 |
Dsm Ip Assets, B.V. |
Biodegradable polyesteramide copolymers for drug delivery
|
US9693957B2
(en)
|
2011-07-08 |
2017-07-04 |
The University Of North Carolina At Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
EP2731970B1
(en)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
CA2843274A1
(en)
|
2011-07-29 |
2013-02-07 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
|
JP6120848B2
(en)
|
2011-08-15 |
2017-04-26 |
メディミューン,エルエルシー |
Anti-B7-H4 antibody and use thereof
|
TW201323440A
(en)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
CA2852536A1
(en)
|
2011-10-24 |
2013-05-02 |
Mannkind Corporation |
Methods and compositions for treating pain
|
KR101999299B1
(en)
|
2011-12-02 |
2019-07-12 |
인티그레이티드 바이오쎄라퓨틱스, 인크. |
Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
|
US20130251703A1
(en)
|
2011-12-05 |
2013-09-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EP2791175A2
(en)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2791173B1
(en)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
WO2013090841A2
(en)
|
2011-12-16 |
2013-06-20 |
Novartis Ag |
Aerosolization apparatus for inhalation profile-independent drug delivery
|
EP3539982A3
(en)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
TW201333035A
(en)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
Dual specific binding proteins directed against IL-13 and/or IL-17
|
KR102129234B1
(en)
|
2012-01-27 |
2020-07-02 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
Composition and method for the diagnosis and treatment of disease associated with neurite degeneration
|
CN107596518B
(en)
|
2012-02-29 |
2021-04-23 |
普马特里克斯营业公司 |
Inhalable dry powder
|
EP2723323B1
(en)
|
2012-03-28 |
2015-09-23 |
Discovery Laboratories, Inc. |
Lyophilization of synthetic liposomal pulmonary surfactant
|
RU2666963C2
(en)
|
2012-04-13 |
2018-09-13 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Aggregated particles
|
AU2013256130B2
(en)
|
2012-05-03 |
2017-12-21 |
Alcon Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US10688041B2
(en)
|
2012-05-03 |
2020-06-23 |
Kala Pharmaceuticals, Inc. |
Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
WO2013184514A1
(en)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
US9802012B2
(en)
|
2012-07-12 |
2017-10-31 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
US10159644B2
(en)
|
2012-10-26 |
2018-12-25 |
Mannkind Corporation |
Inhalable vaccine compositions and methods
|
KR20190107184A
(en)
|
2012-11-01 |
2019-09-18 |
애브비 인코포레이티드 |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
BR112015010601B1
(en)
|
2012-11-09 |
2022-07-19 |
Civitas Therapeutics, Inc. |
PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
|
MX2015005874A
(en)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
|
US10034988B2
(en)
|
2012-11-28 |
2018-07-31 |
Fontem Holdings I B.V. |
Methods and devices for compound delivery
|
BR112015014063A2
(en)
|
2012-12-19 |
2018-10-30 |
Amplimmune Inc |
human anti-b7-h4 antibodies and their uses.
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
EP2935332B1
(en)
|
2012-12-21 |
2021-11-10 |
MedImmune, LLC |
Anti-h7cr antibodies
|
CA2899032A1
(en)
|
2013-02-01 |
2014-08-07 |
Glialogix, Inc. |
Compositions and methods for the treatment of neurodegenerative and other diseases
|
CN115925957A
(en)
|
2013-02-08 |
2023-04-07 |
Irm责任有限公司 |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
EP3763710A1
(en)
|
2013-02-20 |
2021-01-13 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
EP3564384A1
(en)
|
2013-03-14 |
2019-11-06 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
CN105228649B
(en)
|
2013-03-14 |
2019-01-18 |
雅培制药有限公司 |
HCV Ag-Ab combination measurement is with method and used in composition therein
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
CA2903772A1
(en)
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Antibody drug conjugates
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
ES2754388T3
(en)
|
2013-03-15 |
2020-04-17 |
Mannkind Corp |
Compositions and methods of microcrystalline dicetopiperazine
|
BR112015023797A2
(en)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
dual specificity binding proteins directed against il-1b and / or il-17
|
EP2981247B1
(en)
|
2013-04-01 |
2023-06-07 |
Pulmatrix Operating Company, Inc. |
Tiotropium dry powders
|
JP2016518388A
(en)
|
2013-04-30 |
2016-06-23 |
オティトピック インク. |
Dry powder formulation and usage
|
CN106414489A
(en)
|
2013-05-24 |
2017-02-15 |
米迪缪尼有限公司 |
Anti-b7-h5 antibodies and their uses
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
CA2914369C
(en)
|
2013-06-06 |
2023-02-14 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
ES2753419T3
(en)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Complement factor H inhibitors
|
JP6632974B2
(en)
|
2013-06-19 |
2020-01-22 |
インテグレイテッド バイオセラピューティクス,インコーポレイテッド |
Phenol-soluble modulin, delta toxin, toxoid peptide derived from superantigen, and fusion thereof
|
US9925144B2
(en)
|
2013-07-18 |
2018-03-27 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
EP3030294B1
(en)
|
2013-08-05 |
2020-10-07 |
MannKind Corporation |
Insufflation apparatus
|
UA116479C2
(en)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
JP2016533318A
(en)
|
2013-09-17 |
2016-10-27 |
ユニバーシティ ヘルス ネットワーク (ユーエイチエヌ): テクノロジー ディベロップメント アンド コマーシャリゼーション |
Agents targeting RGMA / neogenin cis interaction or lipid rafts and use of the agents in therapeutic methods
|
WO2015042412A1
(en)
|
2013-09-20 |
2015-03-26 |
E-Nicotine Technology. Inc. |
Devices and methods for modifying delivery devices
|
US10287572B2
(en)
|
2013-11-01 |
2019-05-14 |
Regents Of The University Of Minnesota |
Protein scaffolds and methods of use
|
WO2015066482A1
(en)
|
2013-11-01 |
2015-05-07 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
JP6590802B2
(en)
|
2013-11-06 |
2019-10-16 |
ザ ユニバーシティ オブ シカゴThe University Of Chicago |
Nanoscale transporter for delivery or co-delivery of chemotherapeutic drugs, nucleic acids and photosensitizers
|
TWI736515B
(en)
|
2013-11-13 |
2021-08-21 |
美商輝瑞大藥廠 |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
US20150203592A1
(en)
|
2013-12-02 |
2015-07-23 |
Abbvie Inc. |
Compositions and methods for treating osteoarthritis
|
WO2015109012A1
(en)
|
2014-01-14 |
2015-07-23 |
Integrated Biotherapeutics, Inc. |
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
JP6533534B2
(en)
|
2014-02-14 |
2019-06-19 |
マクロジェニクス,インコーポレーテッド |
Composition for use in the treatment of glioblastoma and use thereof
|
CN106102748A
(en)
|
2014-02-20 |
2016-11-09 |
奥迪托皮克股份有限公司 |
For the dry powder formulations sucked
|
EP3110974A4
(en)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
AU2015229463A1
(en)
|
2014-03-12 |
2016-09-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
TW202214691A
(en)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
Anti-egfr antibodies and antibody drug conjugates
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
JP6832709B2
(en)
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
Molecules with modified neonatal Fc receptor binding for enhanced therapeutic and diagnostic properties
|
SG10201913680PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
TWI693232B
(en)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
|
WO2016011167A1
(en)
|
2014-07-16 |
2016-01-21 |
Dana-Farber Cancer Institute, Inc., Et Al |
Her3 inhibition in low-grade serous ovarian cancers
|
CN116687887A
(en)
|
2014-07-31 |
2023-09-05 |
维克图拉公司 |
Dry powder formulations for inhalation
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
US10238748B2
(en)
|
2014-08-12 |
2019-03-26 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
SG10201902499VA
(en)
|
2014-09-03 |
2019-04-29 |
Genesegues Inc |
Therapeutic nanoparticles and related compositions, methods and systems
|
PE20170894A1
(en)
|
2014-09-26 |
2017-07-12 |
Macrogenics Inc |
BI-SPECIFIC MONOVALENT DIACBODIES THAT ARE CAPABLE OF JOINING CD19 AND CD3 AND USING THE SAME
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
ES2924988T3
(en)
|
2014-10-10 |
2022-10-13 |
Univ Michigan Regents |
Compositions with nanoemulsions to prevent, inhibit or eliminate allergic and inflammatory disease
|
CN110731961A
(en)
|
2014-10-14 |
2020-01-31 |
芝加哥大学 |
Metal organic framework, pharmaceutical preparation and use thereof in preparing medicament
|
US10806694B2
(en)
|
2014-10-14 |
2020-10-20 |
The University Of Chicago |
Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
|
CN107106641B
(en)
|
2014-10-31 |
2021-12-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
Powder formulation
|
PT3212169T
(en)
|
2014-10-31 |
2021-05-06 |
Bend Res Inc |
Process for forming active domains dispersed in a matrix
|
MA40910A
(en)
|
2014-11-07 |
2017-09-12 |
Civitas Therapeutics Inc |
RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION
|
KR20170087500A
(en)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
Anti-C10ORF54 antibodies and uses thereof
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
ES2784900T3
(en)
|
2014-12-12 |
2020-10-01 |
Massachusetts Gen Hospital |
Treatment of brain metastases from breast cancer
|
CN107106509B
(en)
|
2014-12-18 |
2021-11-30 |
帝斯曼知识产权资产管理有限公司 |
Drug delivery system for delivering acid sensitive drugs
|
TW201639596A
(en)
|
2015-01-24 |
2016-11-16 |
艾伯維有限公司 |
Compositions and methods for treating psoriatic arthritis
|
AU2015380455A1
(en)
|
2015-01-26 |
2017-08-03 |
Macrogenics, Inc. |
Multivalent molecules comprising DR5-binding domains
|
WO2016120828A1
(en)
|
2015-01-30 |
2016-08-04 |
Novartis Ag |
Treatment of breast cancer by m-csf antagonist
|
AU2016227493B2
(en)
|
2015-03-03 |
2022-01-20 |
Kymab Limited |
Antibodies, uses & methods
|
RU2715597C2
(en)
|
2015-05-29 |
2020-03-02 |
Эббви Инк. |
Antibodies to cd40 and methods of use thereof
|
TWI773646B
(en)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
Lag-3-binding molecules and methods of use thereof
|
TW201710286A
(en)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
Binding proteins against VEGF, PDGF, and/or their receptors
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
CA2991108A1
(en)
|
2015-07-02 |
2017-01-05 |
Civitas Therapeutics, Inc. |
Triptan powders for pulmonary delivery
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
US10328087B2
(en)
|
2015-07-23 |
2019-06-25 |
Therapeuticsmd, Inc. |
Formulations for solubilizing hormones
|
KR20180093127A
(en)
|
2015-07-30 |
2018-08-20 |
마크로제닉스, 인크. |
PD-1-Binding Molecules and Methods of Use Thereof
|
CN116059340A
(en)
|
2015-09-11 |
2023-05-05 |
艾伯维公司 |
Methods for treating relapsing forms of multiple sclerosis
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
EP3359555B1
(en)
|
2015-10-07 |
2023-12-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
IL258521B2
(en)
|
2015-10-08 |
2024-01-01 |
Macrogenics Inc |
Combination therapy for the treatment of cancer
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
MA44334A
(en)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
|
US10875920B2
(en)
|
2015-12-02 |
2020-12-29 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
EP3383908A1
(en)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
SG11201805788WA
(en)
|
2016-02-01 |
2018-08-30 |
Incarda Therapeutics Inc |
Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
|
TW201730212A
(en)
|
2016-02-17 |
2017-09-01 |
宏觀基因股份有限公司 |
ROR1-binding molecules, and methods of use thereof
|
IL292946A
(en)
|
2016-03-02 |
2022-07-01 |
Eisai R&D Man Co Ltd |
Eribulin-based antibody-drug conjugates and methods of use
|
CA3020153A1
(en)
|
2016-04-01 |
2017-10-05 |
Therapeuticsmd, Inc. |
Steroid hormone pharmaceutical composition
|
WO2017173044A1
(en)
|
2016-04-01 |
2017-10-05 |
Therapeuticsmd Inc. |
Steroid hormone compositions in medium chain oils
|
CA3020864A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
WO2017192993A1
(en)
|
2016-05-05 |
2017-11-09 |
Liquidia Technologies, Inc. |
Dry powder treprostinil for the treatment of pulmonary hypertension
|
US11246877B2
(en)
|
2016-05-20 |
2022-02-15 |
The University Of Chicago |
Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
|
US20170349653A1
(en)
|
2016-06-01 |
2017-12-07 |
Abbvie Inc. |
Methods for treating spinal cord injury and pain
|
MX2018014906A
(en)
*
|
2016-06-03 |
2019-08-21 |
M et P Pharma AG |
Nasal pharmaceutical compositions with a porous excipient.
|
BR112018075653A2
(en)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anti-b7-h3 antibodies and drug antibody conjugates
|
LT3458479T
(en)
|
2016-06-08 |
2021-02-25 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CN109475603B
(en)
|
2016-06-20 |
2023-06-13 |
科马布有限公司 |
anti-PD-L1 antibodies
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CN109688818A
(en)
|
2016-09-08 |
2019-04-26 |
卡拉制药公司 |
Crystal form of therapeutic compounds and application thereof
|
TW201818933A
(en)
|
2016-10-21 |
2018-06-01 |
美商吉利亞洛吉克斯公司 |
Compositions and methods for the treatment of neurodegenerative and other diseases
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
JP7274417B2
(en)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1BB binding protein and uses thereof
|
WO2018111580A1
(en)
|
2016-12-13 |
2018-06-21 |
Emory University |
Polypeptides for managing viral infections
|
JOP20190155A1
(en)
|
2016-12-21 |
2019-06-23 |
Novartis Ag |
Antibody drug conjugates for ablating hematopoietic stem cells
|
AU2017382234A1
(en)
|
2016-12-23 |
2019-07-04 |
Macrogenics, Inc. |
ADAM9-binding molecules, and methods of use thereof
|
SG11201906616VA
(en)
|
2017-01-20 |
2019-08-27 |
M et P Pharma AG |
Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
|
WO2018138297A1
(en)
|
2017-01-27 |
2018-08-02 |
Kymab Limited |
Anti-opg antibodies
|
JOP20190187A1
(en)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
Anti-ccr7 antibody drug conjugates
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
EP3612567A4
(en)
|
2017-04-19 |
2020-11-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
AR111651A1
(en)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
KR20200003199A
(en)
|
2017-05-10 |
2020-01-08 |
인카다 테라퓨틱스, 인크. |
Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration
|
EP3630154A4
(en)
|
2017-05-22 |
2021-03-10 |
Insmed Incorporated |
Lipo-glycopeptide cleavable derivatives and uses thereof
|
EP3630835A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
KR20200024158A
(en)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
KR20200026209A
(en)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
|
CN110913883A
(en)
|
2017-06-13 |
2020-03-24 |
综合生物治疗疫苗公司 |
Immunogenic composition comprising Staphylococcus aureus leukocidin LUKA and LUKB derived polypeptides
|
JP7364552B2
(en)
|
2017-08-02 |
2023-10-18 |
ザ ユニバーシティ オブ シカゴ |
Nanoscale metal-organic layers and metal-organic nanoplates for X-ray-induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
|
JP7196850B2
(en)
*
|
2017-09-05 |
2022-12-27 |
味の素株式会社 |
Polylysine derivative
|
US11744967B2
(en)
|
2017-09-26 |
2023-09-05 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal delivery devices
|
JP2021508439A
(en)
|
2017-12-01 |
2021-03-11 |
ノバルティス アーゲー |
Polyomavirus neutralizing antibody
|
SG11202003930YA
(en)
|
2017-12-01 |
2020-05-28 |
Pfizer |
Anti-cxcr5 antibodies and compositions and uses thereof
|
CN112119092A
(en)
|
2018-02-12 |
2020-12-22 |
无糖尿病公司 |
Improved antagonistic anti-human CD40 monoclonal antibodies
|
WO2019173561A1
(en)
*
|
2018-03-08 |
2019-09-12 |
Graham Nichol |
Devices, systems, and methods for delivery of a reperfusion-injury-modifying drug to a patient
|
MX2020009526A
(en)
|
2018-03-12 |
2020-10-28 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof.
|
EP3768378A4
(en)
|
2018-03-22 |
2021-11-17 |
InCarda Therapeutics, Inc. |
A novel method to slow ventricular rate
|
WO2019190984A1
(en)
|
2018-03-29 |
2019-10-03 |
Pfizer Inc. |
Lfa3 variants and compositions and uses thereof
|
US10640576B2
(en)
|
2018-04-10 |
2020-05-05 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
US20190314324A1
(en)
|
2018-04-13 |
2019-10-17 |
The University Of Chicago |
Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
|
CN112165974A
(en)
|
2018-05-31 |
2021-01-01 |
诺华股份有限公司 |
Hepatitis B antibodies
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
IL279062B2
(en)
|
2018-06-01 |
2024-02-01 |
Eisai R&D Man Co Ltd |
Splicing modulator antibody-drug conjugates and methods of use
|
UY38265A
(en)
|
2018-06-20 |
2020-01-31 |
Novartis Ag |
DRUG ANTIBODY CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS
|
US20210268070A1
(en)
|
2018-07-10 |
2021-09-02 |
Rush University Medical Center |
Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds
|
JP2021531007A
(en)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Receptor for VISTA
|
CN112703000A
(en)
|
2018-07-23 |
2021-04-23 |
特雷维治疗股份有限公司 |
Treatment of chronic cough, shortness of breath and dyspnea
|
SG11202100888WA
(en)
|
2018-09-07 |
2021-02-25 |
Pfizer |
Anti-avb8 antibodies and compositions and uses thereof
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
WO2020106358A1
(en)
|
2018-11-20 |
2020-05-28 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
KR20210102274A
(en)
|
2018-12-13 |
2021-08-19 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Herboxidiene Antibody-Drug Conjugates and Methods of Use
|
TW202039554A
(en)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
Anti-tnf-alpha antibodies
|
CA3234463A1
(en)
|
2018-12-21 |
2019-12-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
EP3911739A1
(en)
|
2019-01-16 |
2021-11-24 |
University Of Rochester |
Improvement of epithelial or endothelial barrier function
|
KR102563319B1
(en)
|
2019-03-08 |
2023-08-03 |
앱티스 주식회사 |
Site-specific antibody conjugation, and antibody-drug conjugate as its embodiment
|
AU2020279731A1
(en)
|
2019-05-20 |
2022-01-06 |
Novartis Ag |
Antibody drug conjugates having linkers comprising hydrophilic groups
|
US11020384B2
(en)
|
2019-08-01 |
2021-06-01 |
Incarda Therapeutics, Inc. |
Antiarrhythmic formulation
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
EP4055053A1
(en)
|
2019-11-07 |
2022-09-14 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
KR20220131293A
(en)
|
2020-01-24 |
2022-09-27 |
화이자 인코포레이티드 |
Anti-E-Selectin Antibodies, Compositions and Methods of Use
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
US20230158125A1
(en)
|
2020-04-20 |
2023-05-25 |
Sorrento Therapeutics, Inc. |
Pulmonary Administration of ACE2 Polypeptides
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
CN115461363A
(en)
|
2020-05-01 |
2022-12-09 |
诺华股份有限公司 |
Immunoglobulin variants
|
CN116096758A
(en)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
Engineered immunoglobulins
|
CA3180556A1
(en)
|
2020-05-29 |
2021-12-02 |
Stephan Becker |
Neutralizing antibodies against sars-related coronavirus
|
EP4161966A1
(en)
|
2020-06-05 |
2023-04-12 |
Eisai R&D Management Co., Ltd. |
Anti-bcma antibody-drug conjugates and methods of use
|
AU2021358662A1
(en)
|
2020-10-09 |
2023-05-04 |
Children's Medical Center Corporation |
CD1a ANTIBODIES AND USES THEREOF
|
GB202017058D0
(en)
|
2020-10-27 |
2020-12-09 |
Kymab Ltd |
Antibodies and uses thereof
|
MX2023005234A
(en)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies.
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
CN116472288A
(en)
|
2020-11-06 |
2023-07-21 |
诺华股份有限公司 |
Antibody Fc variants
|
EP4251648A2
(en)
|
2020-11-24 |
2023-10-04 |
Novartis AG |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
EP4259200A1
(en)
|
2020-12-11 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Formulation for multi-purpose application
|
AR124681A1
(en)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
ANTI-EGFR ANTIBODY-DRUG CONJUGATES
|
GB202101125D0
(en)
|
2021-01-27 |
2021-03-10 |
Kymab Ltd |
Antibodies and uses thereof
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
GB202117111D0
(en)
|
2021-11-26 |
2022-01-12 |
Kymab Ltd |
Antibodies for use as therapeutics against bacterial infections
|
EP4190810A1
(en)
|
2021-12-01 |
2023-06-07 |
Universität zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
WO2023099688A1
(en)
|
2021-12-01 |
2023-06-08 |
Universität Zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
WO2023114375A2
(en)
*
|
2021-12-16 |
2023-06-22 |
Alveolus Bio, Inc. |
Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|